See more : Baid Finserv Limited (BAIDFIN.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Evaxion Biotech A/S (EVAX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evaxion Biotech A/S, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- 1CM Inc. (MILFF) Income Statement Analysis – Financial Results
- Bowlin Travel Centers, Inc. (BWTL) Income Statement Analysis – Financial Results
- PharmaCielo Ltd. (PCLO.V) Income Statement Analysis – Financial Results
- MultiPlan Corporation (MPLN) Income Statement Analysis – Financial Results
- Bajaj Finserv Ltd. (BAJAJFINSV.NS) Income Statement Analysis – Financial Results
Evaxion Biotech A/S (EVAX)
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 73.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 112.00 | 571.32K | 343.45K | 105.72K | 80.98K | 73.93K |
| Gross Profit | 72.89K | -571.32K | -343.45K | -105.72K | -80.98K | -73.93K |
| Gross Profit Ratio | 99.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.92M | 17.06M | 19.58M | 10.90M | 8.22M | 3.73M |
| General & Administrative | 10.35M | 8.21M | 6.25M | 5.67M | 2.63M | 1.88M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.35M | 8.21M | 6.25M | 5.67M | 2.63M | 1.88M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 15.00K |
| Operating Expenses | 22.25M | 25.26M | 25.83M | 16.57M | 10.86M | 5.63M |
| Cost & Expenses | 22.27M | 25.26M | 25.83M | 16.57M | 10.86M | 5.63M |
| Interest Income | 154.00K | 2.83M | 2.04M | 216.00K | 9.00K | 2.00K |
| Interest Expense | 897.00K | 1.51M | 915.00K | 223.00K | 1.22M | 698.00K |
| Depreciation & Amortization | 615.95K | 571.32K | 343.45K | 105.72K | 80.98K | 73.93K |
| EBITDA | -21.40M | -22.58M | -24.17M | -16.46M | -11.90M | -6.18M |
| EBITDA Ratio | -29,319.18% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -22.20M | -25.26M | -25.83M | -16.57M | -10.86M | -5.63M |
| Operating Income Ratio | -30,406.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -718.00K | 1.32M | 1.12M | -7.00K | -1.16M | -636.93K |
| Income Before Tax | -22.92M | -23.94M | -24.71M | -16.58M | -12.02M | -6.27M |
| Income Before Tax Ratio | -31,390.41% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -791.22K | -772.00K | -178.00K | -1.56M | -825.00K | -735.00K |
| Net Income | -22.13M | -23.17M | -24.53M | -15.02M | -11.20M | -5.54M |
| Net Income Ratio | -30,308.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -8.11 | -9.80 | -12.58 | -9.27 | -6.91 | -2.88 |
| EPS Diluted | -8.11 | -9.80 | -12.58 | -9.27 | -6.91 | -2.88 |
| Weighted Avg Shares Out | 2.73M | 2.36M | 1.95M | 1.62M | 1.62M | 1.92M |
| Weighted Avg Shares Out (Dil) | 2.73M | 2.36M | 1.95M | 1.62M | 1.62M | 1.92M |
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
COPENHAGEN, Denmark, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, proudly announces the presentation of its novel precision vaccine concept at the 65th...
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
COPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, presents for the first time its AI model designed to predict patient responses...
Evaxion Shares Latest EVX-01 Phase 2 Clinical Data in Webinar with Key Opinion Leader Adnan Khattak
COPENHAGEN, Denmark, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in the development of AI-Immunology™ powered vaccines, is hosting an online webinar featuring Key Opinion Leader (KOL) and...
New and Exciting Clinical Data on Evaxion's AI-Immunology™-Based Personalized Cancer Vaccines to be Presented
COPENHAGEN, Denmark, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™-powered vaccines, is proud to announce that it will be presenting clinical readouts on its two...
Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
COPENHAGEN, Denmark, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that the Company received a letter (the “Notification Letter”) on...
Evaxion (EVAX) Up on Partnership With Afrigen for Gonorrhea Jab
Evaxion's (EVAX) shares gain as it collaborates with Afrigen Biologics to develop prophylactic mRNA vaccine targeting gonorrhea, based on Evaxion's EDEN technology.
Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea
COPENHAGEN, Denmark, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced a collaboration with Afrigen Biologics (Afrigen). The collaboration aims at...
Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company
COPENHAGEN, Denmark, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation of a novel pipeline program, EVX-B3, an AI-designed...
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
COPENHAGEN, Denmark, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, has achieved a groundbreaking milestone in vaccine discovery with the validation of...
Evaxion announces Executive Management Changes to strengthen the AI-strategy
COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced:
Source: https://incomestatements.info
Category: Stock Reports